-
PetMeds® Announces Fiscal 2024 Third Quarter Financial Results and Completion of Financial Restatement
15 Apr 2024 12:16 GMT
Fiscal 2024 3Q Revenue of $65.3 million, an 11% increase compared to last year including PetCareRx results.
AutoShip & Save and PetPlus Membership, 52% of total revenue, up from 42% at the same time last year.
Strong balance sheet with $49.4 million of …
-
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
17 Apr 2024 14:27 GMT
… Expected in the Third Quarter of 2024
CAMBRIDGE, … safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) … analogue).
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is … while increasing energy expenditure, thus potentially resulting …
-
Neogen Announces Third-Quarter 2024 Results
09 Apr 2024 14:07 GMT
Revenue of $228.8 million.
Net loss of $(2.0) million; $(0.01) per diluted share.
Adjusted Net Income of $26.4 million; $0.12 per diluted share.
Adjusted EBITDA of $52.7 million.
Updating full-year outlook.
LANSING, Mich., April 9, 2024 /PRNewswire…
-
Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results
09 Apr 2024 11:00 GMT
… (Tilray Pharma) gross margin was 10% in the third quarter compared … notable achievements during the third quarter, including growing revenue … expertise. During the third quarter, international cannabis net … amount of capital expenditures that are considered …
-
OceanFirst Financial Corp. (NASDAQ:OCFC) Q1 2024 Earnings Call Transcript
22 Apr 2024 13:44 GMT
… at the end of the third quarter (see the details here). Operator … a very well-known national pharmaceutical company and another very well … business line, maybe some capital expenditure purchases. But we’re seeing …
-
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Call Transcript
02 Apr 2024 14:49 GMT
… at the end of the third quarter (see the details here). … with Alvogen and Lotus Pharmaceuticals, to develop our lead … Therapeutics as a specialty pharmaceutical company to advance and … consistently reduced our cash expenditures and expect to further …
-
Gujarat pharma majors maintain growth momentum
02 Apr 2024 02:59 GMT
… like Lincoln Pharma, Sun Pharma Advance Research Co … pharma companies viz., Sun Pharmaceuticals, Zydus Lifesciences, Torrent Pharma, Alembic Pharmaceuticals … Its R&D expenditure reached at Rs. … pharma major, launched 18 products during the third quarter …
-
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
01 Apr 2024 14:28 GMT
… , Inc. and Lotus Pharmaceuticals
-- Elected nationally recognized … to decrease its ongoing expenditure associated with manufacturing and … succeeded.
Accordingly, in Q3 the Company finalized a … 0920.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical- …
-
Patterson Companies Reports Fiscal 2024 Third Quarter Operating Results
28 Feb 2024 12:28 GMT
… value creation potential.”
Third Quarter Fiscal 2024 Results
… activities less capital expenditures plus the collection … captioned, GAAP measures.
Third Quarter Conference Call and Replay
… the distribution of pharmaceuticals and controlled substances; …
-
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
22 Mar 2024 20:05 GMT
… plan implemented in the third quarter of 2023. Research and … that began in the third quarter of 2023. Costs … not commenced. About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a … may impact its cash expenditures; the uncertainties inherent in …